Published in Prostate on January 12, 2011
A human prostatic bacterial isolate alters the prostatic microenvironment and accelerates prostate cancer progression. J Pathol (2015) 1.45
Prostatic inflammation enhances basal-to-luminal differentiation and accelerates initiation of prostate cancer with a basal cell origin. Proc Natl Acad Sci U S A (2013) 1.43
Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem (2011) 1.12
Does the microenvironment influence the cell types of origin for prostate cancer? Genes Dev (2013) 0.97
CCL2 and CCL3 are essential mediators of pelvic pain in experimental autoimmune prostatitis. Am J Physiol Regul Integr Comp Physiol (2012) 0.96
Pten null prostate epithelium promotes localized myeloid-derived suppressor cell expansion and immune suppression during tumor initiation and progression. Mol Cell Biol (2014) 0.89
Upregulation of androgen-responsive genes and transforming growth factor-β1 cascade genes in a rat model of non-bacterial prostatic inflammation. Prostate (2013) 0.85
Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity. J Immunol (2015) 0.84
Nociceptive and inflammatory mediator upregulation in a mouse model of chronic prostatitis. Pain (2015) 0.81
Low CD38 Identifies Progenitor-like Inflammation-Associated Luminal Cells that Can Initiate Human Prostate Cancer and Predict Poor Outcome. Cell Rep (2016) 0.81
Characterization of autoimmune inflammation induced prostate stem cell expansion. Prostate (2015) 0.81
Development of animal models underlining mechanistic connections between prostate inflammation and cancer. World J Clin Oncol (2013) 0.79
Impact of prostate inflammation on lesion development in the POET3(+)Pten(+/-) mouse model of prostate carcinogenesis. Am J Pathol (2014) 0.79
Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. Prostate (2014) 0.78
Inflammation promotes prostate differentiation. Proc Natl Acad Sci U S A (2014) 0.78
Immunological tolerance to muscle autoantigens involves peripheral deletion of autoreactive CD8+ T cells. PLoS One (2012) 0.78
Re: An inducible model of abacterial prostatitis induces antigen specific inflammatory and proliferative changes in the murine prostate. J Urol (2012) 0.75
Inflammation and cancer. Nature (2002) 53.78
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Inflammation in prostate carcinogenesis. Nat Rev Cancer (2007) 9.08
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med (2007) 5.65
NIH consensus definition and classification of prostatitis. JAMA (1999) 5.35
Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci U S A (1998) 4.40
T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A (2001) 3.15
How common is prostatitis? A national survey of physician visits. J Urol (1998) 2.90
Genetic susceptibility to post-thymectomy autoimmune diseases in mice. Immunogenetics (1981) 2.80
Chronic inflammation in benign prostate hyperplasia is associated with focal upregulation of cyclooxygenase-2, Bcl-2, and cell proliferation in the glandular epithelium. Prostate (2004) 2.19
Self tolerance and localized autoimmunity. Mouse models of autoimmune disease that suggest tissue-specific suppressor T cells are involved in self tolerance. J Exp Med (1987) 2.14
Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol (2001) 1.82
Induction of tissue-specific autoimmune prostatitis with prostatic acid phosphatase immunization: implications for immunotherapy of prostate cancer. J Immunol (1997) 1.80
Inflammation in benign prostatic hyperplasia: a 282 patients' immunohistochemical analysis. Prostate (2009) 1.73
Augmentation of T cell levels and responses induced by androgen deprivation. J Immunol (2004) 1.71
Quality of life is impaired in men with chronic prostatitis: the Chronic Prostatitis Collaborative Research Network. J Gen Intern Med (2001) 1.64
CD4 and CD8 T-lymphocyte recognition of prostate specific antigen in granulomatous prostatitis. J Immunother (2004) 1.54
National institutes of Health Chronic Prostatitis Symptom Index for Japanese men. Urology (2002) 1.48
Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology (1997) 1.26
Epidemiology of prostatitis: new evidence for a world-wide problem. World J Urol (2003) 1.24
Pain sensitization in male chronic pelvic pain syndrome: why are symptoms so difficult to treat? J Urol (2003) 1.21
Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem (2008) 1.14
Experimental rodent models of prostatitis: limitations and potential. Prostate Cancer Prostatic Dis (2007) 1.08
Prevalence of prostatitis-like symptoms in a managed care population. J Urol (2006) 1.06
Mouse model for acute bacterial prostatitis in genetically distinct inbred strains. Urology (2005) 1.06
Prevalence of prostatitis-like symptoms in Singapore: a population-based study. Singapore Med J (2002) 1.03
Urinary symptomatology in younger men. Urology (1997) 1.02
Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate. Br J Cancer (2009) 1.02
An aberrant prostate antigen-specific immune response causes prostatitis in mice and is associated with chronic prostatitis in humans. J Clin Invest (2009) 1.01
T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate (2006) 1.00
Non-obese diabetic (NOD) mice are genetically susceptible to experimental autoimmune prostatitis (EAP). J Autoimmun (1998) 1.00
Leukocytic promotion of prostate cellular proliferation. Prostate (2010) 0.98
Prostatitis. J Urol (2007) 0.98
Treatment of prostatitis in the rat. Prostate (1984) 0.98
Deletion is neither sufficient nor necessary for the induction of peripheral tolerance in mature CD8+ T cells. Immunology (2006) 0.97
Spontaneous and prostatic steroid binding protein peptide-induced autoimmune prostatitis in the nonobese diabetic mouse. J Immunol (2007) 0.97
Intraepithelial and stromal lymphocytes in the normal human prostate. Prostate (2003) 0.96
Chronic prostatitis: symptom survey with follow-up clinical evaluation. Urology (2003) 0.96
Physiologic self antigens rapidly capacitate autoimmune disease-specific polyclonal CD4+ CD25+ regulatory T cells. Blood (2005) 0.96
Presence of INFgamma-secreting lymphocytes specific to prostate antigens in a group of chronic prostatitis patients. Clin Immunol (2005) 0.94
Comparison of the activation status of tumor infiltrating and peripheral lymphocytes of patients with adenocarcinomas and benign hyperplasia of the prostate. Prostate (2000) 0.91
Identification of rat prostatic steroid-binding protein as a target antigen of experimental autoimmune prostatitis: implications for prostate cancer therapy. J Immunol (1997) 0.90
Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training. J Urol (2006) 0.89
Perinatal exposure to estrogenic compounds and the subsequent effects on the prostate of the adult rat: evaluation of inflammation in the ventral and lateral lobes. Reprod Toxicol (2000) 0.88
Prostatitis in the rat. Scand J Urol Nephrol (1979) 0.87
Intraprostatic lymphocyte profiles in aged wistar rats with estradiol induced prostate inflammation. J Urol (2006) 0.79
Disruption of the CFTR gene produces a model of cystic fibrosis in newborn pigs. Science (2008) 6.28
Deletion of brain dystroglycan recapitulates aspects of congenital muscular dystrophy. Nature (2002) 3.96
Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol (2009) 3.78
Cystic fibrosis pigs develop lung disease and exhibit defective bacterial eradication at birth. Sci Transl Med (2010) 3.36
Origins of cystic fibrosis lung disease. N Engl J Med (2015) 2.97
The porcine lung as a potential model for cystic fibrosis. Am J Physiol Lung Cell Mol Physiol (2008) 2.53
Disease phenotype of a ferret CFTR-knockout model of cystic fibrosis. J Clin Invest (2010) 2.45
The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy. Immunity (2012) 2.15
Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer (2009) 2.13
Biofilm-infected wounds in a dog. J Am Vet Med Assoc (2014) 2.12
T-cell immunoglobulin and mucin domain 1 (TIM-1) is a receptor for Zaire Ebolavirus and Lake Victoria Marburgvirus. Proc Natl Acad Sci U S A (2011) 2.12
The ΔF508 mutation causes CFTR misprocessing and cystic fibrosis-like disease in pigs. Sci Transl Med (2011) 2.01
Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration. Cell (2002) 2.01
Implementation of virtual microscope slides in the annual pathobiology of cancer workshop laboratory. Hum Pathol (2003) 2.01
Foxp3+ CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J Immunol (2010) 1.88
Platelet-mediated modulation of adaptive immunity. A communication link between innate and adaptive immune compartments. Immunity (2003) 1.84
Platelet-mediated modulation of adaptive immunity: unique delivery of CD154 signal by platelet-derived membrane vesicles. Blood (2008) 1.83
Multiple lineages of human breast cancer stem/progenitor cells identified by profiling with stem cell markers. PLoS One (2009) 1.82
Unique role of dystroglycan in peripheral nerve myelination, nodal structure, and sodium channel stabilization. Neuron (2003) 1.80
Cell of origin strongly influences genetic selection in a mouse model of T-ALL. Blood (2011) 1.78
Pathologist workforce in the United States: I. Development of a predictive model to examine factors influencing supply. Arch Pathol Lab Med (2013) 1.78
Diurnal cortisol variations and symptoms in patients with interstitial cystitis. J Urol (2002) 1.73
Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nat Commun (2013) 1.73
Air trapping and airflow obstruction in newborn cystic fibrosis piglets. Am J Respir Crit Care Med (2013) 1.65
Assessing tumor growth and distribution in a model of prostate cancer metastasis using bioluminescence imaging. Clin Exp Metastasis (2006) 1.64
Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J Virol (2006) 1.59
Aberration in the expression of the retinoid receptor, RXRalpha, in prostate cancer. Cancer Biol Ther (2003) 1.58
Trichostatin A (TSA) sensitizes the human prostatic cancer cell line DU145 to death receptor ligands treatment. Cancer Biol Ther (2005) 1.54
Epithelial-to-mesenchymal transition in prostate cancer: paradigm or puzzle? Nat Rev Urol (2011) 1.53
ZEB1 enhances transendothelial migration and represses the epithelial phenotype of prostate cancer cells. Mol Biol Cell (2009) 1.52
Dystroglycan loss disrupts polarity and beta-casein induction in mammary epithelial cells by perturbing laminin anchoring. J Cell Sci (2006) 1.49
Mesial temporal lobe epilepsy: pathogenesis, induced rodent models and lesions. Toxicol Pathol (2007) 1.48
Cholesterol sulfate imaging in human prostate cancer tissue by desorption electrospray ionization mass spectrometry. Anal Chem (2010) 1.48
MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biol Ther (2008) 1.48
TRAIL-DISC formation is androgen-dependent in the human prostatic carcinoma cell line LNCaP. Cancer Biol Ther (2003) 1.47
Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE. J Biol Chem (2009) 1.46
Coauthorship in pathology, a comparison with physics and a survery-generated and member-preferred authorship guideline. MedGenMed (2004) 1.45
Bisindolylmaleimide IX Induces Reversible and Time-Dependent Tumor Necrosis Factor Receptor Family-Mediated Caspase Activation and Cell Death. Cancer Biol Ther (2003) 1.40
Abnormal endocrine pancreas function at birth in cystic fibrosis ferrets. J Clin Invest (2012) 1.40
Platelet-derived CD154 enables T-cell priming and protection against Listeria monocytogenes challenge. Blood (2008) 1.40
Commentary: Mentoring the mentor: executive coaching for clinical departmental executive officers. Acad Med (2010) 1.38
In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol (2011) 1.37
Dystroglycan is selectively associated with inhibitory GABAergic synapses but is dispensable for their differentiation. J Neurosci (2002) 1.33
Cutting edge: mutation of Francisella tularensis mviN leads to increased macrophage absent in melanoma 2 inflammasome activation and a loss of virulence. J Immunol (2010) 1.33
Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry. Prostate (2002) 1.32
Transepithelial migration of neutrophils into the lung requires TREM-1. J Clin Invest (2012) 1.31
Intestinal CFTR expression alleviates meconium ileus in cystic fibrosis pigs. J Clin Invest (2013) 1.30
Multiple CD4+ T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. J Immunol (2011) 1.30
Enhanced surfactant protein and defensin mRNA levels and reduced viral replication during parainfluenza virus type 3 pneumonia in neonatal lambs. Clin Diagn Lab Immunol (2004) 1.25
Expression of EphA2 and Ephrin A-1 in carcinoma of the urinary bladder. Clin Cancer Res (2006) 1.24
Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol (2007) 1.24
IL-13 is required for eosinophil entry into the lung during respiratory syncytial virus vaccine-enhanced disease. J Immunol (2008) 1.24
The emerging role of platelets in adaptive immunity. Cell Immunol (2006) 1.19
Phosphoinositol phosphatase SHIP2 promotes cancer development and metastasis coupled with alterations in EGF receptor turnover. Carcinogenesis (2007) 1.16
Interpreting stress responses during routine toxicity studies: a review of the biology, impact, and assessment. Toxicol Pathol (2013) 1.15
Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol (2009) 1.15
Mandatory second opinion in surgical pathology referral material: clinical consequences of major disagreements. Am J Surg Pathol (2008) 1.14
Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α. Proc Natl Acad Sci U S A (2014) 1.14
Prostate inflammation and its potential impact on prostate cancer: a current review. J Cell Biochem (2008) 1.14
Disruption of perlecan binding and matrix assembly by post-translational or genetic disruption of dystroglycan function. FEBS Lett (2005) 1.12
ZEB1 coordinately regulates laminin-332 and {beta}4 integrin expression altering the invasive phenotype of prostate cancer cells. J Biol Chem (2010) 1.12
Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem (2011) 1.12
Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene (2005) 1.12
Differential expression of ovine innate immune genes by preterm and neonatal lung epithelia infected with respiratory syncytial virus. Viral Immunol (2006) 1.11
Advancing translational research. Science (2011) 1.11
Cooperation of two mutant p53 alleles contributes to Fas resistance of prostate carcinoma cells. Cancer Res (2003) 1.10
Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis. Cancer Res (2006) 1.09
Modulation of reactive oxygen species by Rac1 or catalase prevents asbestos-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2009) 1.09
Fat dogs and coughing horses: K-12 programming for veterinary workforce development. J Vet Med Educ (2013) 1.08
Achieving successful deployment of Bt rice. Trends Plant Sci (2004) 1.06
Baby shampoo nasal irrigations for the symptomatic post-functional endoscopic sinus surgery patient. Am J Rhinol (2008) 1.06
Letters to the editor. Endocr Pract (2015) 1.06
Death receptor-induced cell death in prostate cancer. J Cell Biochem (2004) 1.05
Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for bioluminescence imaging of tumor response to therapy. Cancer Res (2007) 1.05
Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther (2007) 1.04
Runx2 regulates survivin expression in prostate cancer cells. Lab Invest (2009) 1.03
Preparation of 66Ga- and 68Ga-labeled Ga(III)-deferoxamine-folate as potential folate-receptor-targeted PET radiopharmaceuticals. Nucl Med Biol (2003) 1.03
Role of FcRgamma and factor XIIIA in coated platelet formation. Blood (2005) 1.02
Plk1 phosphorylation of orc2 and hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol Cancer Ther (2012) 1.02
Impact of small fitness costs on pest adaptation to crop varieties with multiple toxins: a heuristic model. J Econ Entomol (2006) 1.02
Development of a porcine model of cystic fibrosis. Trans Am Clin Climatol Assoc (2009) 1.02
Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res (2002) 1.02
Sinus hypoplasia precedes sinus infection in a porcine model of cystic fibrosis. Laryngoscope (2012) 1.02
Maternal alcohol ingestion reduces surfactant protein A expression by preterm fetal lung epithelia. Alcohol (2007) 1.02
Prostatic intraepithelial neoplasia in mice with conditional disruption of the retinoid X receptor alpha allele in the prostate epithelium. Cancer Res (2002) 1.02
Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Mol Cancer Res (2006) 1.02
Mouse prostate cancer cell lines established from primary and postcastration recurrent tumors. Horm Cancer (2010) 1.01
Phase I clinical trial of an adenovirus/prostate-specific antigen vaccine for prostate cancer: safety and immunologic results. Clin Cancer Res (2009) 1.01
Slow disease progression in a C57BL/6 pten-deficient mouse model of prostate cancer. Am J Pathol (2011) 1.01
T-cell recognition of a prostate specific antigen is not sufficient to induce prostate tissue destruction. Prostate (2006) 1.00